Steep Hill Inc. operates in the healthcare sector, previously focusing on cannabis science. The company shows strong liquidity with a current ratio of 15.76 and no debt, indicating financial stability. However, it faces concerns with negative returns on equity and assets, reflecting operational inefficiencies. The recent price increase of 8.57% may suggest speculative interest, but the low market cap of $7.71M raises questions about long-term viability. Overall, while liquidity is a strength, the lack of significant operations and negative financial returns are notable concerns.
Loading financial metrics...
Operating cash flow has been negative for 3 consecutive quarters, burning $147K over the last year.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 15.8x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q2 (June 30, 2025)